Check out your Company Bowl for anonymous work chats.
The College of Paramedics Opens Dr John Hinds Scholarship Call for Entries February 1, 2022 Craigavon, N.I., Tuesday 1st Febraury 2022– The College of Paramedics, in association with Galen, the privately-owned pharmaceutical sales and marketing company is pleased to announce that applications for this year’s Dr John Hinds Scholarship Award will open on Monday 31st January 2022. The recipient will win a place on the much-coveted Anaesthesia Trauma and Critical Care (ATACC) course and have their case study published in the College of Paramedics’ magazine, ‘Paramedic INSIGHT’.
Almac Group Recognised in Life Science Leader CMO Awards for the Eighth Time
Almac Diagnostic Services’ claraT Report Assists Researchers In Uncovering New Oncology Findings Publications from US and UK-based researchers could lead to better future therapeutic outcomes in brain and breast cancer Craigavon, N.I., Wednesday 8 December 2021 – Almac Diagnostic Services, a member of the Almac Group, is delighted to announce that its unique software driven solution for gene expression data analysis – claraT – has assisted oncology researchers at The University of Arkansas for Medical Sciences (US) and Queen’s University Belfast (UK) in the study of brain and breast cancers. The studies, recently published in the MDPI Cancer Journal and the British Journal of Cancer, have the potential to lead to better therapeutic outcomes for patients.
Almac Group Reaffirms Commitment to Reducing Global Plastic Pollution Craigavon, Northern Ireland – 24 November 2021 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, is proud to announce that the company has enhanced its engagement with the Responsible Plastics Management (RPM) Program, an internationally recognised, not-for-profit membership organisation set up by certificate and sustainability experts to tackle the plastic pollute crisis.
Craigavon, N.I. – Almac Group, the global contract pharmaceutical development and manufacturing organisation, is planning to recruit 1,800 new jobs across its global operations over the next three years. These new jobs include operational, supervisory and managerial roles across its business and offers an exciting variety of opportunities for both graduates and experienced candidates alike. Positions are available immediately across 120 different job roles at its sites in the UK, Ireland, North America, Singapore, Japan and the Nordic region.
Continuing to expand technology capabilities through Innovate UK funded Knowledge Transfer Partnership Craigavon, Northern Ireland – 22nd September 2021 – Almac Sciences, a member of the Almac Group, has successfully reached the midway point of its continuous flow technology project made possible through an Innovate UK funded Knowledge Transfer Partnership (KTP) in partnership with Queen’s University Belfast. The aim of the Innovate UK funded KTP is to further enhance established flow technologies platforms at Almac Sciences. The technology will be used for development and manufacture of key raw materials and unlock capacity to perform challenging chemical transformations. The KTP scheme supports business growth through identification of new skills and transfer of the latest academic concepts to deliver a strategic innovation programme.
Scholarship established in partnership with Triangle Community Foundation to support next generation Durham, North Carolina – 2 September 2021 – Almac Group is delighted to announce that Khadeeja Ali Syeda, a 2021 graduate of Apex Friendship High School, has been selected as the recipient of the inaugural Almac Group Scholarship, and will receive $50,000 over the next four years. After an independent review by Triangle Community Foundation’s seasoned scholarship committee, Khadeeja was named this year’s recipient due to her impressive academic performance and involvement in the community, interest in pursuing a STEM career, and powerful personal statement. She will attend North Carolina State University and will receive, in addition to tuition assistance, mentorship opportunities and unique exposure to Almac Group’s career opportunities in the global pharmaceutical and biotech industry.
Almac Sciences, global provider of integrated drug development services and member of the Almac Group, is delighted to announce that the company has signed a manufacturing agreement with Swedish biotech company, PILA PHARMA, for the production of XEN-D0501 active pharmaceutical ingredient (API). From its global headquarter facilities in Northern Ireland, Almac Sciences will manufacture XEN-D0501, a highly selective and very potent small molecule TRPV1 antagonist, previously in development by Bayer Healthcare and Xention/Ario Pharma. The TRPV1 target (also called the “chili-receptor”) has demonstrated applications across pain and inflammatory diseases and possibly in diabetes as well. XEN-D0501 was acquired by PILA PHARMA in March 2016, and subsequently, PILA PHARMA has demonstrated good safety results as well as efficacy, i.e. a statistically improved endogenous insulin response to oral glucose versus placebo in patients with type 2 diabetes, thus demonstrating proof of principle of XEN-D0501.
Almac Clinical Technologies, a member of the contract and development organization, Almac Group, and THREAD, a technology and service provider enabling decentralized clinical trials (DCTs), and today announced a strategic partnership. The market leaders will integrate their technologies to enable more efficient clinical trials that generate better outcomes. By integrating their proprietary technology platforms, Almac and THREAD will provide sponsors and contract research organizations (CROs) with a full range of tools to reduce the risk of trial delays. Almac’s IXRS™ solution and industry-leading services for randomization and clinical trial supply management will be available to THREAD customers and THREAD’s DCT solution will be available to Almac customers. The two companies will leverage single sign-on and application program interfaces (APIs) to integrate their technologies and automate DCT workflows across their respective platforms to: • minimize duplicate data entry, particularly for research sites • provide sponsors with integrated reports on trial progress • preserve autom
Almac Group’s Turnover Increases by £43M to £677M in 2020 Craigavon, N.I., 07 Jun 2021 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, has reported a £43 million (6%) rise in turnover from £634.3 million in 2018/19 to £677.3 million for its financial year 2019/20. During this period, the revenue increase resulted in improved pre-tax profits which were recorded at £63.5 million, up from £47.6 million for the same period the previous year. Group performance in 2020 was enhanced through the receipt of a number of out-licencing payments from products developed in-house. Average employee figures increased from 5,150 to 5,466 during the same period. These figures were recorded in the organisation’s annual report for year ending 30 September 2020. Throughout this year, Almac invested significantly in both new and existing facilities to meet ongoing global demand for its unique, high-quality solutions.
